Drug compounders aren’t ready to give up their ability to produce off-brand versions of Novo Nordisk’s weight-loss drug ...

The case is pending in the U.S. District Court for the District of New Jersey and is captioned Moon v. Novo Nordisk A/S, et al., No. 25-cv-00713. Why was Novo Nordisk Sued for Securities Fraud?

The case, filed in the U.S. District Court for the District of New Jersey under the title Moon v. Novo Nordisk A/S, No. 25-cv-00713, alleges that the company and its key executives committed ...

The FDA’s decision will threaten the ability of compounding pharmacies to make far cheaper, unbranded versions of the ...

[email protected] 844-916-0895 Novo Nordisk A/S (NVO) Securities Class Action: The suit, filed in the U.S. District Court for the District of New Jersey and captioned Moon v. Novo Nordisk A/S ...

Novo Nordisk announced that the U.S. Food and Drug Administration (FDA) has determined the shortage of Wegovy® and Ozempic® is resolved. The FDA's assessment confirms the U.S. supply of these ...

Novo Nordisk reported strong data for its next-gen anti-obesity medicine. The Danish company has an excellent weight loss drug pipeline. But it's also diversifying its lineup and offering other perks.

The long-running U.S. shortage of Novo Nordisk's blockbuster weight loss injection Wegovy and diabetes treatment Ozempic is resolved after more than two years, the U.S. Food and Drug ...